Kisunla vs. Leqembi: A Comparative Overview

Let’s compare Kisunla and Leqembi, two drugs used in the treatment of Alzheimer’s disease:

1. Drug Class:

• • Kisunla:
    • • Belongs to a new class of drugs designed to slow the progression of Alzheimer’s disease.
    • • A monoclonal antibody that targets beta-amyloid, the toxic protein that accumulates in the brains of Alzheimer’s patients, forming plaques that disrupt normal brain signaling.

• • Leqembi:
    • • Also a monoclonal antibody targeting beta-amyloid.
    • • Approved last year for certain patients with early Alzheimer’s disease.

2. Approval:

• • Kisunla:
    • • FDA approved on July 2, 2024¹.
    • • Infused once a month.

• • Leqembi:
    • • Approved earlier.
    • • Administered twice a month¹.

3. Effectiveness:

• • Kisunla:
    • • May slow declines in memory and thinking skills in early-stage Alzheimer’s patients.
    • • Cannot reverse memory loss or other symptoms.
    • • Not a cure.

• • Leqembi:
    • • Similar effects to Kisunla.

4. Brain Scans:

• • Kisunla:
    • • Patients can stop taking the drug after PET brain scans show minimal beta-amyloid levels (unlike Leqembi, where patients continue treatment).
    • • In the clinical trial, nearly half of those who received Kisunla stayed at the same cognitive level after one year¹.

Remember that neither drug can reverse existing brain damage, and benefits are modest. Consult your doctor to determine the best treatment for your specific situation. 🧠

Learn more:

1. alzinfo.org
2. pbs.org
3. apnews.com
4. biospace.com